Business
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities.\n\n\nDr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-in-class launches. He joins Janux at an important stage as the Company advances its pipeline and continues to scale its clinical and regulatory operations.\n\n\nMost recently, Dr. Go served as Chief Medical Officer at A2 Biotherapeutics, where he led development of logic-gated CAR T-cell therapies for solid tumors. During his tenure, A2 Bio initiated three Phase 1 clinical trials across multiple solid tumor indications.\n\n\nPreviously, Dr. Go held senior leadership roles at Kite Pharma, where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA®, the first CAR T-cell therapy approved for large B-cell lymphoma. Following Kite’s acquisition by Gilead Sciences, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma.\n\n\nEarlier in his career at Amgen, Dr. Go contributed to the global label expansion of Vectibix® and helped advance extended RAS next-generation sequencing strategies in colorectal cancer to identify predictive biomarkers.\n\n\nDr. Go earned a B.A. in Biology from Carleton College and completed an M.D. and Ph.D. through the UC San Diego Medical Scientist Training Program. He completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes.\n\n\n“Janux is entering an important new phase as our programs advance and the complexity of our clinical and regulatory efforts increases,” said David Campbell, Ph.D., President and C...